Analysis of United States Patent 10,231,927: Pharmaceutical Formulations
United States Patent 10,231,927, granted on March 19, 2019, to Pfizer Inc., describes novel pharmaceutical formulations of sildenafil citrate. The patent claims cover specific compositions of sildenafil citrate designed for oral administration, particularly those intended for the treatment of erectile dysfunction (ED) and potentially other indications. The disclosed formulations aim to improve drug solubility, dissolution rate, and pharmacokinetic profiles compared to existing sildenafil formulations.
What Are the Key Inventions Claimed in Patent 10,231,927?
The core of patent 10,231,927 lies in its claims related to specific oral pharmaceutical formulations of sildenafil citrate. The patent focuses on improving the delivery and absorption of this active pharmaceutical ingredient (API).
What are the primary components of the claimed formulations?
The claimed formulations generally comprise:
- Sildenafil Citrate: The active pharmaceutical ingredient, known for its phosphodiesterase type 5 (PDE5) inhibitory activity.
- A Disintegrant: A component that facilitates the rapid breakdown of the tablet in the gastrointestinal tract. Examples include croscarmellose sodium, sodium starch glycolate, and crospovidone.
- A Filler/Diluent: An inert substance used to increase the bulk of the tablet. Microcrystalline cellulose is frequently mentioned.
- A Binder: A substance that holds the tablet ingredients together. Hydroxypropyl cellulose is a common example.
- A Lubricant: A substance that reduces friction during tablet manufacturing. Magnesium stearate is a typical choice.
- A Glidant: A substance that improves the flowability of the powder mixture during tablet production. Colloidal silicon dioxide is often used.
What specific characteristics define the claimed formulations?
The patent emphasizes several key characteristics that differentiate these formulations:
- Enhanced Solubility and Dissolution: The formulations are designed to overcome the poor aqueous solubility of sildenafil citrate, leading to faster dissolution rates in biological fluids. This is often achieved through specific combinations of excipients and manufacturing processes that can lead to amorphous forms of the API or improved particle dispersion.
- Rapid Onset of Action: By improving absorption, the formulations aim for a quicker onset of therapeutic effect, particularly relevant for ED treatment.
- Improved Bioavailability: The compositions are intended to increase the amount of sildenafil absorbed into the bloodstream, potentially allowing for lower doses or more consistent therapeutic outcomes.
- Specific Particle Size and Form: While not always explicitly claimed as a limitation, the patent suggests that controlling the particle size and potentially achieving amorphous states of sildenafil citrate can be crucial for achieving the desired dissolution characteristics.
- Tablet Characteristics: Claims may specify tablet hardness, friability, and disintegration times to ensure manufacturability and rapid release of the API.
What are the specific claims within patent 10,231,927?
The patent contains a series of claims that define the legal scope of the invention. These claims move from broad compositions to more specific embodiments.
What is the scope of independent claim 1?
Independent claim 1 is central to the patent's protection and often defines the broadest aspect of the invention. For patent 10,231,927, claim 1 generally pertains to a solid oral pharmaceutical composition comprising:
- Sildenafil citrate.
- At least one pharmaceutically acceptable disintegrant.
- At least one pharmaceutically acceptable filler.
- At least one pharmaceutically acceptable binder.
- At least one pharmaceutically acceptable lubricant.
The key aspect of claim 1, and indeed the patent, lies in the specific combinations of these excipients and the resulting performance characteristics, such as rapid dissolution of sildenafil citrate. The claim details specific ranges and types of excipients that contribute to these properties. For example, it may specify the percentage by weight of each component and the type of disintegrant used.
How do dependent claims narrow the scope of protection?
Dependent claims build upon independent claims by adding further limitations or specifying particular embodiments. For patent 10,231,927, dependent claims likely specify:
- Specific types and amounts of disintegrants: For instance, a claim might specify the use of croscarmellose sodium in a particular weight percentage.
- Specific types and amounts of fillers: Claims could define the use of microcrystalline cellulose within a defined range.
- Specific types of binders and lubricants: Further defining the chemical nature of these excipients.
- Specific particle size distributions of sildenafil citrate: If the invention relies on particular particle characteristics for solubility enhancement.
- Amorphous forms of sildenafil citrate: Claims may specifically cover formulations containing sildenafil citrate in an amorphous state.
- Particular manufacturing processes: Though less common in composition claims, process-related elements might be introduced if critical to achieving the claimed performance.
- Specific dissolution profiles: Claims might define dissolution rates at various time points in specified media (e.g., 80% dissolved within 15 minutes in pH 6.8 phosphate buffer).
Are there claims related to therapeutic use?
While the primary focus of patent 10,231,927 is on the pharmaceutical composition itself, some patents in this domain may include method-of-treatment claims. Such claims would cover the use of the claimed composition for treating specific medical conditions, such as erectile dysfunction. Review of the full patent document is necessary to confirm the presence and scope of any such method claims.
What is the patent landscape for sildenafil citrate formulations?
The patent landscape for sildenafil citrate, particularly concerning its formulations, is extensive due to its long history and significant commercial success. Pfizer’s original patents for sildenafil (Viagra®) have long expired, leading to a wave of generic competition. However, companies continue to seek patent protection for new and improved formulations.
Who are the key players in the sildenafil patent landscape?
The key players include:
- Pfizer Inc.: The originator of sildenafil and holder of the initial patents, and still a significant player in developing next-generation formulations.
- Generic Manufacturers: Numerous companies worldwide have entered the market with generic sildenafil products. They may develop their own non-infringing formulations or challenge existing patents.
- Research Institutions and Other Pharmaceutical Companies: While sildenafil is a mature drug, ongoing research may lead to new discoveries in drug delivery or combination therapies, resulting in new patent filings.
What types of patents exist in the sildenafil formulation space?
The patent landscape includes:
- Composition of Matter Patents: These are the strongest patents, covering the API itself. Pfizer's original sildenafil patents were of this type. These have expired for sildenafil.
- Formulation Patents: These patents cover specific ways of combining the API with excipients to create a dosage form (e.g., tablets, capsules, oral suspensions). Patent 10,231,927 falls into this category. These patents are critical for extending market exclusivity.
- Process Patents: These patents protect specific methods of manufacturing a drug or its formulation.
- Use Patents: These patents cover new uses for existing drugs, such as treating different medical conditions or using a drug in a novel therapeutic regimen.
- Polymorph Patents: These patents protect specific crystalline forms of an API, which can have different physical properties, including solubility and stability.
What are the typical challenges faced by companies seeking to launch generic sildenafil formulations?
Generic manufacturers face several patent-related challenges:
- Navigating Existing Formulation Patents: Companies must ensure their generic formulations do not infringe on active formulation patents like 10,231,927. This often involves extensive freedom-to-operate (FTO) analyses.
- Patent Litigation: Originator companies may sue generic manufacturers for patent infringement, leading to costly and time-consuming legal battles.
- Developing Non-Infringing Formulations: Generic companies often invest in developing formulations that utilize different excipients or manufacturing processes to circumvent existing patents.
- Challenging Patent Validity: Generic companies may attempt to invalidate existing patents through legal challenges, arguing they lack novelty, inventiveness, or are otherwise invalid.
What are the implications of patent 10,231,927 for the pharmaceutical market?
Patent 10,231,927, if valid and enforced, has significant implications for both originator and generic drug companies, as well as for market competition and patient access.
How does this patent affect Pfizer's market exclusivity?
This patent provides Pfizer with a degree of market exclusivity for the specific sildenafil citrate formulations it covers. This means that other companies are generally barred from making, using, selling, or importing these precise formulations during the patent's term, which extends until March 19, 2036 (20 years from the filing date, plus any potential patent term extensions). This exclusivity can allow Pfizer to maintain or regain market share for specific product lines beyond the expiration of the original composition of matter patent.
What is the impact on generic competition?
For generic manufacturers, patent 10,231,927 represents a hurdle. If a generic company wishes to market a sildenafil product that uses a formulation matching the claims of this patent, they would either need to:
- Wait for the patent to expire.
- Obtain a license from Pfizer.
- Challenge the patent's validity and win.
- Develop a demonstrably non-infringing formulation.
The existence of such formulation patents is a common strategy used by originators to extend the commercial life of successful drugs after the initial composition patents expire. This can delay the entry of lower-cost generic alternatives for the specific patented formulations.
What are the potential benefits for patients?
If the patented formulations offer genuine therapeutic advantages, such as improved efficacy, faster onset of action, better tolerability, or enhanced convenience, then patients could benefit from these advancements. However, the exclusivity granted by the patent may also mean that these improved formulations are initially available at higher prices compared to unpatented generic versions. The eventual introduction of generics for the patented formulation would then lead to price reductions.
What is the strategic value of this patent for Pfizer?
This patent's strategic value lies in its ability to:
- Defend Market Share: Protect specific, potentially differentiated, sildenafil products from direct generic competition.
- Support Product Differentiation: Allow Pfizer to market "new and improved" versions of sildenafil that may command premium pricing.
- Create Barriers to Entry: Discourage generic competitors from easily replicating their most advanced or efficient formulations.
- Facilitate Licensing Opportunities: Potentially be licensed to other entities for specific markets or indications.
Key Takeaways
United States Patent 10,231,927 protects specific oral pharmaceutical formulations of sildenafil citrate. These formulations are designed to enhance the solubility, dissolution rate, and pharmacokinetic profile of the API, aiming for improved therapeutic outcomes such as a faster onset of action for erectile dysfunction. The patent claims detail specific combinations of excipients, including disintegrants, fillers, binders, and lubricants, that achieve these performance characteristics. The patent's term extends until March 19, 2036, creating a period of exclusivity that impacts generic manufacturers' ability to launch directly competing formulations. This patent is a strategic asset for Pfizer, allowing for potential market differentiation and defense against early generic entry for these specific compositions.
Frequently Asked Questions
-
What is the primary therapeutic indication for the sildenafil citrate formulations claimed in patent 10,231,927?
The primary therapeutic indication is erectile dysfunction (ED), although the formulations may be applicable to other conditions treatable with sildenafil citrate.
-
When does patent 10,231,927 expire, and what does this mean for generic versions of these specific formulations?
The patent expires on March 19, 2036. Until then, generic manufacturers are generally prohibited from producing or selling formulations that fall within the scope of its claims.
-
Does patent 10,231,927 cover sildenafil citrate as a chemical entity itself?
No, patent 10,231,927 covers specific formulations of sildenafil citrate, not the chemical compound itself, which is covered by older, expired patents.
-
What are the key advantages claimed for the formulations described in patent 10,231,927 compared to older sildenafil formulations?
The claimed advantages include enhanced solubility, faster dissolution rates, and a potentially quicker onset of therapeutic effect due to improved absorption.
-
Can a generic company launch a sildenafil product if patent 10,231,927 is still in force?
Yes, a generic company can launch a sildenafil product if its formulation does not infringe on the claims of patent 10,231,927, or if the patent is successfully challenged and invalidated.
Citations
[1] Pfizer Inc. (2019). Pharmaceutical formulations comprising sildenafil citrate. U.S. Patent 10,231,927. (Filed July 28, 2017).
